Neutropenic enterocolitis: Difference between revisions

No edit summary
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
==Background==
==Background==
[[File:Diameters of the large intestine.png|thumb|Average inner diameters and ranges of different sections of the large intestine.<ref> Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, et al. (July 2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of Visualized Experiments (41). doi:10.3791/1931. PMC 3149991. PMID 20689513.</ref>]]
*Also known as "typhlitis"
*Necrosis of bowel wall secondary to polymicrobial invasion
*Necrosis of bowel wall secondary to polymicrobial invasion
**Involves terminal ileum and colon
**Involves terminal ileum and colon
**May progress to full-thickness infarction/perforation
**May progress to full-thickness infarction/perforation
*Occurs 10-14d after cytotoxic therapy


==Clinical Features==
==Clinical Features==
*Fever
*Typically presents 10-14d after cytotoxic therapy
*RLQ pain
*[[neutropenic fever|Fever]]
*Nausea
*[[RLQ pain]]
*Vomiting
*[[Nausea/vomiting]]


==Differential Diagnosis==
==Differential Diagnosis==
Line 17: Line 18:
==Evaluation==
==Evaluation==
===Workup<ref>Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.</ref>===
===Workup<ref>Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.</ref>===
*CBC with neutropenia, thrombocytopenia
*CBC with [[neutropenia]], [[thrombocytopenia]]
*Blood cultures positive in ~25-85%, frequently bowel organisms
*Blood cultures positive in ~25-85%, frequently bowel organisms
*CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
*CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
Line 24: Line 25:
==Management==
==Management==
*Bowel rest
*Bowel rest
*NG tube to suction
*[[NG tube]] to suction
*IVF
*[[IVF]]
*TPN
*TPN
*Consider G-CSF, particularly neutropenia < 100/ml and severe disease<ref>Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.</ref>
*Consider G-CSF, particularly neutropenia < 100/ml and severe disease<ref>Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.</ref>
Line 45: Line 46:
[[Category:GI]]
[[Category:GI]]
[[Category:ID]]
[[Category:ID]]
[[category:Surgery]]
[[Category:Heme/Onc]]

Latest revision as of 21:10, 24 September 2025

Background

Average inner diameters and ranges of different sections of the large intestine.[1]
  • Also known as "typhlitis"
  • Necrosis of bowel wall secondary to polymicrobial invasion
    • Involves terminal ileum and colon
    • May progress to full-thickness infarction/perforation

Clinical Features

Differential Diagnosis

Oncologic Emergencies

Related to Local Tumor Effects

Related to Biochemical Derangement

Related to Hematologic Derangement

Related to Therapy

RLQ Pain

Evaluation

Workup[2]

  • CBC with neutropenia, thrombocytopenia
  • Blood cultures positive in ~25-85%, frequently bowel organisms
  • CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
  • Avoid endoscopic evaluation due to risk of perforation, hemorrhage, bacterial translocation, worsening sepsis

Management

  • Bowel rest
  • NG tube to suction
  • IVF
  • TPN
  • Consider G-CSF, particularly neutropenia < 100/ml and severe disease[3]
  • Broad spectrum antimicrobials, in particular against gut microbiota to include[4]:
  • Surgical consult (possible need for right hemicolectomy)[5]

Disposition

  • Admit

See Also

References

  1. Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, et al. (July 2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of Visualized Experiments (41). doi:10.3791/1931. PMC 3149991. PMID 20689513.
  2. Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.
  3. Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.
  4. Gorschluter M, Mey U, Strehl J, Zinske C, Schepke M, Schmid F, Wolf IG, Sauerbruch T, Glasmacher A, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13.
  5. Williams N, Scott AD. Neutropaenic enterocolitis : a continuing surgical challenge. Br J Surg. 1997;84(9):1200–1205.